<DOC>
	<DOCNO>NCT01086488</DOCNO>
	<brief_summary>Objectives : Primary objective - To determine efficacy Foscan-PDT compare Brachytherapy recurrent persistent NPC , determine macroscopic clinical examination , CT scan biopsy . The primary endpoint complete tumour response 6 month . Secondary objective : - To determine response rate , e.g . presence tumour endoscopy , time progression overall survival patient treat Foscan-PDT compare brachytherapy - To determine quality life , derive University Washington Quality Life questionnaire patient treat Foscan-PDT compare brachytherapy - To evaluate safety Foscan-PDT compare brachytherapy term adverse event serious adverse event .</brief_summary>
	<brief_title>Foscan®-Mediated Photodynamic Therapy Versus Brachytherapy Patients With Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>This multi-centre , randomize , control Phase II study assess use Foscan®-mediated photodynamic therapy versus Brachytherapy patient recurrent persistent nasopharyngeal carcinoma . The start point PDT arm study parameter recommend treatment patient squamous cell carcinoma head neck . These parameter ( drug dose , 0.1 mg/kg Foscan® ; drug-light interval , 48 hour ; light dose , 20 J/cm2 50 mW ) show effective limited number treatment perform patient nasopharyngeal carcinoma . Patients evaluate regular basis 12 week follow treatment . Patients persistent tumour ( confirm histologically , clinically possible ) 12 week follow treatment , adequate clinical assessment tumour response possible , may retreat Foscan® . A maximum two Foscan®-PDT treatment may administer single patient . Patients follow 24 month follow final Foscan®-PDT treatment . Study population Any patient recurrent persistent nasopharyngeal carcinoma , least 3 month follow full course irradiation , eligible assessment enrolment study provide tumour less equal 15 mm depth accessible unrestricted illumination use nasopharyngeal applicator . Diagnosis cancer , first instance , make clinical inspection site . The diagnosis must confirm histologically . All patient full assessment diagnostic workup accordance usual departmental practice , include CT scan skull base neck . The study centre keep log patient screen evaluated inclusion study document reason patient include select .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Temoporfin</mesh_term>
	<criteria>Patients deem eligible inclusion follow criterion meet . Histologically confirm local locoregional recurrent persistent NPC , [ T12a , N12 ; M0 ] least 3 month follow full course irradiation Discrete tumour , less equal 15 mm depth , endoscopically visible accessible unrestricted surface illumination use nasopharyngeal applicator , bony invasion Patient 18 69 year age , legally competent Patient ECOG performance status ≤2 Patient man nonpregnant , nonlactating woman Patient , legally appoint representative , able willing provide inform consent participate study Patients deem eligible inclusion follow criterion apply . Elective surgery plan within 30 day administration Foscan® Patient disease , cause exacerbated light , include systemic lupus erythematosus , psoriasis , porphyria , actinic reticuloid xeroderma pigmentosum Patient treat within prior 30 day lightactivated therapy medication may render patient photosensitive ( e.g. , psoralen ultraviolet Arange [ PUVA ] , Accutane ) Patient receive prior photodynamic therapy propose treatment site within prior 3 month Patient coexist ophthalmic disease , likely require slit lamp examination within 30 day follow Foscan® administration Patient know hypersensitivity temoporfin , excipients , porphyrins Patient tumour know erode major blood vessel , adjacent , propose illumination site Patient childbearing potential use adequate contraceptive protection . Patient practice strict birth control ( oestrogencontaining oral contraceptive intrauterine device ) throughout study . Only postmenopausal woman ( least 2 year since onset menopause ) woman hysterectomy exempt requirement use birth control . Patient receive treatment experimental drug within prior 30 day Patient receive radiotherapy head neck region within prior 3 month Patient willing able complete visit requirement protocol adhere instruction regard light exposure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>recurrent persistent Nasopharyngeal Carcinoma</keyword>
	<keyword>treatment patient squamous cell carcinoma head neck</keyword>
	<keyword>Foscan-PDT</keyword>
	<keyword>Brachytherapy</keyword>
</DOC>